Compare Invesco DB Agriculture Fund (DBA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs TG Therapeutics Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.33 (market cap $1.32B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 6.2× Invesco DB Agriculture Fund's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and TG Therapeutics Inc for 16 Days on average.
| DBA | TGTX | |
|---|---|---|
Market Cap | $1.32B | $8.16B |
Volume | 771,657 | 1,735,121 |
52-Week High | $29.49 | $59.06 |
52-Week Low | $25.44 | $26.94 |
Typical Hold Time | 24 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA trades at $28.34, down 0.53% with a bearish technical signal from moving averages. The ETF has delivered strong YTD performance of 12.4%, matching the S&P 500, driven by agricultural commodity strength and geopolitical catalysts. Recent consolidation near highs reflects mixed sentiment with neutral oscillators but solid momentum indicators.
The agricultural ETF faces headwinds from high expense ratios (0.85%) and commodity volatility, but benefits from weather risks and global demand. Analyst consensus leans neutral with geopolitical developments and El Niño impacts presenting both opportunities and risks for continued outperformance in agricultural markets.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
